The U.S. Food and Drug Administration in White Oak, Md., on June 5, 2023. Madalina Vasiliu/The Epoch Times
The Food and Drug Administration is defending its choice not to move forward with reviewing a therapy for a rare brain issue called Huntington’s disease.
We had a problem loading this article. Please enable javascript or use a different browser. If the issue persists, please visit our help center.
Read Full Article: https://www.theepochtimes.com/health/fda-defends-demand-for-new-trial-for-rare-brain-disease-therapy-5995270/?utm_source=partner&utm_campaign=whatfinger
